<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diagn Pathol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diagn Pathol</journal-id>
      <journal-title-group>
        <journal-title>Diagnostic Pathology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1746-1596</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25183312</article-id>
      <article-id pub-id-type="pmc">4167136</article-id>
      <article-id pub-id-type="publisher-id">163</article-id>
      <article-id pub-id-type="doi">10.1186/s13000-014-0163-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Deeply located low-grade fibromyxoid sarcoma with FUS-CREB3L2 gene fusion in a 5-year-old boy with review of literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kurisaki-Arakawa</surname>
            <given-names>Aiko</given-names>
          </name>
          <address>
            <email>akurisa@juntendo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suehara</surname>
            <given-names>Yoshiyuki</given-names>
          </name>
          <address>
            <email>ysuehara@juntendo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Arakawa</surname>
            <given-names>Atsushi</given-names>
          </name>
          <address>
            <email>aatsushi@juntendo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takagi</surname>
            <given-names>Tatsuya</given-names>
          </name>
          <address>
            <email>ttatsuya@juntendo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takahashi</surname>
            <given-names>Michiko</given-names>
          </name>
          <address>
            <email>mctakaha@juntendo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mitani</surname>
            <given-names>Keiko</given-names>
          </name>
          <address>
            <email>k-mitani@juntendo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kaneko</surname>
            <given-names>Kazuo</given-names>
          </name>
          <address>
            <email>k-kaneko@juntendo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yao</surname>
            <given-names>Takashi</given-names>
          </name>
          <address>
            <email>tyao@juntendo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Saito</surname>
            <given-names>Tsuyoshi</given-names>
          </name>
          <address>
            <email>tysaitou@juntendo.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Human Pathology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo Japan </aff>
        <aff id="Aff2"><label/>Department of Orthopaedic Surgery, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>3</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>3</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>9</volume>
      <elocation-id>163</elocation-id>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Kurisaki-Arakawa et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Low-grade fibromyxoid sarcoma (LGFMS) is a rare soft tissue tumor typically affecting young to middle-aged adults. Despite its otherwise benign histologic appearance and indolent nature, it can have fully malignant behavior, and recurrence and metastasis may occur even decades later.</p>
        </sec>
        <sec>
          <title>Case history</title>
          <p>We report a case of LGFMS in the left lower leg of a 5-year-old Japanese boy. A magnetic resonance imaging (MRI) uncovered a well-demarcated intra-gastrocnemial tumor measuring 27&#x2009;&#xD7;&#x2009;20&#xA0;mm with a slightly high intensity on T1WI and heterogeneously high intensity on T2WI. Histologically, the tumor was composed of bland spindle-shaped cells with a whorled growth pattern. The tumor stroma was variably hyalinized and fibromyxoid with arcades of curvilinear capillaries and arterioles with associated perivascular fibrosis. Although LGFMS is known to affect children under 18&#xA0;years of age, it is extremely rare in infants and children under 5&#xA0;years of age. Despite the young age, this patient was accurately diagnosed by the typical histology and the detection of a FUS-CREB3L2 gene fusion.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Although LGFMS in children tends to be located superficially, this case presented with an intramuscular tumor in the region of the gastrocnemius. To the best of our knowledge, this is the first case of deep LGFMS arising in a child younger than 5&#xA0;years of age. The patient is still alive with no evidence of the disease 4&#xA0;months after diagnosis.</p>
        </sec>
        <sec>
          <title>Virtual Slides</title>
          <p>The virtual slide(s) for this article can be found here: <ext-link ext-link-type="uri" xlink:href="http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_163">http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_163</ext-link></p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Low-grade fibromyxoid sarcoma</kwd>
        <kwd>FUS-CREB3L2</kwd>
        <kwd>Fusion gene</kwd>
        <kwd>Young patients</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>Low-grade fibromyxoid sarcoma (LGFMS) is a rare soft tissue tumor that typically affects young to middle-aged adults [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>]. The median age of onset for LGFMS is 34&#xA0;years [<xref ref-type="bibr" rid="CR3">3</xref>], although patients of any age can be affected, and 13-19% of cases occur in patients 18&#xA0;years and younger [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>]. However, LGFMS is rare in children during the first 5&#xA0;years of life [<xref ref-type="bibr" rid="CR2">2</xref>]. To the best of our knowledge, the youngest case of LGFMS is a tumor arising from the cheek in a 22-month-old girl [<xref ref-type="bibr" rid="CR4">4</xref>]. Histologically, LGFMS is composed of bland spindle-shaped cells in a whorled growth pattern, arranged in alternating myxoid and collagenized areas along with curvilinear capillaries and characteristic arterioles with perivascular fibrosis. Although most of the tumor cells show benign histological appearance, approximately 10% of the tumor may have scattered large, hyperchromatic and pleomorphic nuclei [<xref ref-type="bibr" rid="CR1">1</xref>]. Furthermore, approximately 40% of cases have focal areas of hypocellular collagen cores rimmed by epithelioid fibroblasts, referred to as collagen pseudo-rosettes. Cases with prominent collagen pseudo-rosettes are referred to as hyalinizing spindle cell tumor with giant rosettes [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p>In spite of its otherwise benign histologic appearance and indolent progression, many cases of the LGFMS may recur or metastasize decades later, mainly to the lung. Therefore, it is important to make a correct diagnosis and provide long-term follow-up for LGFMS patients. However, a diagnosis of LGFMS is often difficult because of a small biopsy specimen that can lead to a misdiagnosis of malignant tumors as benign or as tumor-like lesions including nodular fasciitis, schwannoma, desmoid-type fibromatosis, neurofibroma, and myxofibrosarcoma [<xref ref-type="bibr" rid="CR6">6</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>Although, LGFMS is negative for most immunohistochemical markers, a recent study identified up-regulation of the mucin 4 (MUC4) gene in LGFMS compared with histologically similar tumors and lesions [<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref>], and MUC4 immunostaining was a sensitive and specific marker of LGFMS in the appropriate morphologic context [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref>]. Additionally, it has been described that claudin-1, which was associated with tight junction protein, and epithelial membrane antigen (EMA) were negative for LGFMS [<xref ref-type="bibr" rid="CR10">10</xref>] with exceptional positivity for LGFMS with perineuriomatous component [<xref ref-type="bibr" rid="CR11">11</xref>]. Perineurioma is a benign soft tissue tumor, derived from perineural cells which differ from other mesenchymal cells by virtue of their formation of tight junctions [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
      <p>Several recent studies demonstrated that greater than 90% of LGFMS have a balanced chromosomal translocation t (7;16) (q32-34;p11) leading to the fusion of the FUS and CREB3L2, while a minority of cases have a t(11;16) (p11;p11) translocation leading to the fusion of the FUS and CREB3L1 [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref>&#x2013;<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref>]. In one report, a small number of LGFMS cases contained EWSR-CREB3L1 gene fusions [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p>We report a case of a 5-year-old Japanese boy with deeply located LGFMS in the lateral aspect of the lower leg. The diagnosis of LGFMS was confirmed by the presence of the characteristic FUS-CREB3L2 gene fusion using reverse transcription polymerase chain reaction (RT-PCR) from a formalin-fixed, paraffin-embedded (FFPE) biopsy specimen.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 5-year-old Japanese boy was referred to our hospital with a painless mass in the lateral aspect of the left lower leg. An MRI revealed a well-demarcated intra-gastrocnemial tumor measuring 20&#x2009;&#xD7;&#x2009;27&#xA0;mm with slightly high intensity on T1WI and heterogeneously high intensity on T2WI (Figures&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>A and <xref rid="Fig1" ref-type="fig">1</xref>B). Histopathologically, the tumor was composed of bland spindle-shaped cells with a whorled growth pattern on the biopsy specimen. The tumor stroma was variably hyalinized and fibromyxoid with arcades of curvilinear capillaries and arterioles with perivascular fibrosis (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>A-<xref rid="Fig2" ref-type="fig">2</xref>C). The tumor showed no nuclear pleomorphism, high cellularity, or necrosis, and had few mitoses. Differential diagnosis on conventional H&amp;E staining included desmoid-type fibromatosis, schwannoma, and LGFMS. Immunohistochemically, the tumor cells were negative for S-100 protein and nuclear staining of beta-catenin, typically present in desmoid-type fibromatosis. The Ki67 proliferation index was approximately 20% (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>D and <xref rid="Fig2" ref-type="fig">2</xref>E). Moreover, we performed immunohistochemical staining for MUC4 (sc-53945, Santa-Cruz Biotechnology, Dallas, TX, 1:100, mouse monoclonal), claudin-1 (Product# LS-B6327, LifeSpan Biosciences, Seattle, WA, 1:200, rabbit polyclonal) and EMA (E29, DAKO, Grostrup, Denmark, 1:100, mouse, monoclonal) on this case. Tumor cells showed diffuse, strong cytoplasmic immunoreactivity for MUC4. On the other hand, the tumor did not show immunoreactivity for claudin-1 and EMA in line with the absence of perineuriomatous component (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>F and <xref rid="Fig2" ref-type="fig">2</xref>G).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>MRI of lower left leg of the 5-year-old patient.</bold> An axial view MRI revealed a well-defined mass measuring 27&#x2009;&#xD7;&#x2009;20&#xA0;mm in the lateral aspect of the gastrocnemius. The mass had slightly high intensity compared to the skeletal muscle on T1WI <bold>(A)</bold> and a heterogeneously high intensity on T2WI <bold>(B)</bold>.</p></caption><graphic xlink:href="13000_2014_163_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Tumor Histology.</bold> An admixture of myxoid and fibrous areas was observed on H&amp;E staining <bold>(A)</bold>. Higher magnification views of myxoid <bold>(B)</bold> and fibrous <bold>(C)</bold> components of the tumor. A whorled growth pattern with bland spindle-shaped tumor cells was observed. Immunoreactivity for nuclear &#x3B2;-catenin was absent <bold>(D)</bold>. Ki67 staining was present with a proliferative index of approximately 20% <bold>(E)</bold>. Tumor cells showed diffuse and strong immunoreactivity for MUC4 <bold>(F)</bold>. Tumor was negative for claudin-1 <bold>(G)</bold>.</p></caption><graphic xlink:href="13000_2014_163_Fig2_HTML" id="MO2"/></fig></p>
      <p>To determine if the FUS-CREB3L1 and FUS-CREB3L2 fusion genes were present in the tumor, we performed RT-PCR from FFPE tumor tissue. Briefly, five 10-&#x3BC;m thick paraffin sections were cut from the paraffin-embedded block. RNA was isolated using the RNeasy FFPE kit (QIAGEN, Hilden, Germany). Purified RNA was reverse transcribed to cDNA using the Superscript first-strand synthesis system for RT-PCR (Invitrogen, CA, USA). The primer sequences used for the amplification in this study were described previously [<xref ref-type="bibr" rid="CR14">14</xref>]. The PCR product was separated on a 2% agarose gel, and a PCR product of the appropriate size was cut from the gel and sequenced. Sequencing confirmed a gene fusion between exon 6 of the FUS and exon 5 of CREB3L2 (Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). Despite the young age of the patient, a diagnosis of LGFMS was confirmed, and the patient subsequently underwent wide resection at the affected area. Macroscopically, the resected surface of the surgical specimen was gray with a glistening appearance (Figure&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Pathological analysis of the resected tumor confirmed the LGFMS histology observed in the biopsy specimen. Four months after diagnosis, the patient is alive with no evidence of the disease.<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Detection of a FUS-CREB3L2 fusion in the LGFMS tumor.</bold> RT-PCR on FFPE-derived RNA was performed. DNA sequencing revealed a fusion between FUS exon 6 and CREB3L2 exon 5.</p></caption><graphic xlink:href="13000_2014_163_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Gross morphology of LGFMS from the 5-year-old patient.</bold> The resected surface of intramuscular tumor is tan to gray colored and has a glistening appearance. The tumor is located in the subcutis and skeletal muscle throughout the fascia.</p></caption><graphic xlink:href="13000_2014_163_Fig4_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>The importance of molecular pathological diagnosis is increasing in the clinical pathology, especially in the field of soft tissue sarcomas, because the definite diagnosis made by the molecular pathology such as RT-PCR and specific genetic testing sometimes leads to the application of the tumor specific therapy [<xref ref-type="bibr" rid="CR15">15</xref>&#x2013;<xref ref-type="bibr" rid="CR17">17</xref>]. Recently, LGFMS was shown to be associated with gene fusions involving CREB3-family genes that encode members of the basic leucine zipper family of transcription factors [<xref ref-type="bibr" rid="CR2">2</xref>]. The majority of LGFMS cases (95%) have a fusion of the FUS-CREB3L2, and a minority of cases (5%) have a FUS-CREB3L1 gene fusion. In addition, a small number of cases have EWSR-CREB3L1 gene fusions [<xref ref-type="bibr" rid="CR5">5</xref>]. Because of its typical histology and the presence of a FUS-CREB3L2 fusion, we were able to correctly diagnose LGFMS, despite the atypical age of the patient. LGFMS can affect patients of all ages, and 13-19% of the cases occur in patients younger than 18&#xA0;years of age [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>]. Nonetheless, desmoid-type fibromatosis would be the most important differential diagnosis in this deeply located tumor. Desmoid-type fibromatosis is a locally aggressive infiltrative intra-muscular tumor, in spite of benign histologic feature. Frequent recurrences can be clinically observed even after wide resection. A &#x201C;wait-and-see&#x201D; strategy is, at the present time, preferred in case of asymptomatic or non-progressive disease, especially for the patients of young age. Medical treatment such as cyclooxygenase-2 selective inhibitor is another choice for the patients with desmoid-type fibromatosis [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
      <p>LGFMS is extremely rare in children younger than 5&#xA0;years of age [<xref ref-type="bibr" rid="CR2">2</xref>], and we found only 34 LGFMS cases in children under 15&#xA0;years of age reported in English literatures. The clinical, histological, and genetic information of the previously reported cases are summarized in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR4">4</xref>&#x2013;<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR19">19</xref>&#x2013;<xref ref-type="bibr" rid="CR27">27</xref>]. Nine cases up to 5&#xA0;years of age were found including the present case. In our review of LGFMS in infants and young adolescents, the male to female ratio was 7:2 in infants (0-5 years of age) and 8:5 in young adolescents (6-15 years of age). In adult cases, the male to female ratio was reported to be either equal [<xref ref-type="bibr" rid="CR7">7</xref>] or 3:1 [<xref ref-type="bibr" rid="CR28">28</xref>]. The greatest mean tumor diameter was 3.7&#xA0;cm in both infants and young adolescents, and this was smaller than that found in adult cases (mean 7.7&#xA0;cm) [<xref ref-type="bibr" rid="CR4">4</xref>]. LGFMS tends to be located superficially in young patients, whereas deep LGFMS accounts for the majority of adult cases [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR7">7</xref>]. Superficial LGFMS was reported to account for no more than 10% of LGFMS cases in all ages [<xref ref-type="bibr" rid="CR4">4</xref>]; however, it was found in 73% of the patients 15&#xA0;years and younger in our literature review, in line with the previous finding [<xref ref-type="bibr" rid="CR22">22</xref>]. Particularly, in patients 5&#xA0;years of age or younger in which information for the depth of the tumor was available, all cases were located superficially, and our case was the only one that was deeply located.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Literature review of LGFMS of children (&#x2266;15 y. o.)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th valign="middle">
<bold>Case</bold>
</th><th valign="middle">
<bold>Age</bold>
</th><th valign="middle">
<bold>Sex</bold>
</th><th valign="middle">
<bold>Site</bold>
</th><th valign="middle">
<bold>Location</bold>
</th><th valign="middle">
<bold>Size</bold>
</th><th valign="middle">
<bold>Genetic abnormality</bold>
</th><th valign="middle">
<bold>Characteristic feature</bold>
</th><th valign="middle">
<bold>Recurrence</bold>
</th><th valign="middle">
<bold>Reference</bold>
</th></tr></thead><tbody><tr valign="top"><td valign="middle" align="center">1</td><td valign="middle" align="center">10</td><td valign="middle" align="center">M</td><td valign="middle" align="center">back</td><td valign="middle" align="center">subcutis</td><td valign="middle" align="center"/><td valign="middle" align="center">FUS gene rearrangement (+) by FISH</td><td valign="middle" align="center">pleomorphism (+)</td><td valign="middle" align="center"/><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR1">1</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">2</td><td valign="middle" align="center">8</td><td valign="middle" align="center">M</td><td valign="middle" align="center">pelvis</td><td valign="middle" align="center">subfascial</td><td valign="middle" align="center">&#x3C6;80mm</td><td valign="middle" align="center">(&#x2212;)</td><td valign="middle" align="center"/><td valign="middle" align="center">local recurrence and intra abdominal meta 8 mos later</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">3</td><td valign="middle" align="center">14</td><td valign="middle" align="center">M</td><td valign="middle" align="center">brachium</td><td valign="middle" align="center">subfascial</td><td valign="middle" align="center">&#x3C6;50mm</td><td valign="middle" align="center">(&#x2212;)</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">4</td><td valign="middle" align="center">14</td><td valign="middle" align="center">M</td><td valign="middle" align="center">brachium</td><td valign="middle" align="center">subfascial</td><td valign="middle" align="center">&#x3C6;30mm</td><td valign="middle" align="center">FUS gene rearrangement (+) by FISH</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">5</td><td valign="middle" align="center">6</td><td valign="middle" align="center">M</td><td valign="middle" align="center">Lower leg</td><td valign="middle" align="center">subcutis</td><td valign="middle" align="center">&#x3C6;10mm</td><td valign="middle" align="center">EWSR1 (Ex9)/ CREB3L1 (Ex5) fusion gene by RT-PCR</td><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;)</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR5">5</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">6</td><td valign="middle" align="center">13</td><td valign="middle" align="center">M</td><td valign="middle" align="center">popliteal fossa</td><td valign="middle" align="center">deep</td><td valign="middle" align="center"/><td valign="middle" align="center">FUS/ CREB3L1 fusion gene by array-CGH</td><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;)</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR12">12</xref>]</td></tr><tr valign="top"><td valign="middle" align="center" rowspan="2">7</td><td valign="middle" align="center" rowspan="2">3</td><td valign="middle" align="center" rowspan="2">M</td><td valign="middle" align="center" rowspan="2">thigh</td><td valign="middle" align="center" rowspan="2">subcutis</td><td valign="middle" align="center" rowspan="2">17&#x2009;&#xD7;&#x2009;16&#x2009;&#xD7;&#x2009;12&#xA0;mm</td><td valign="middle" align="center">FUS gene rearrangement (+) by FISH and</td><td valign="middle" align="center">unusual histology+</td><td valign="middle" align="center" rowspan="2">recurrence 1&#xA0;year later</td><td valign="middle" align="center" rowspan="2">[<xref ref-type="bibr" rid="CR2">2</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">other chromosomal translocations (7q34, 10q11.2, 16p11.2)</td><td valign="middle" align="center">calponin (+)</td></tr><tr valign="top"><td valign="middle" align="center">8</td><td valign="middle" align="center">5</td><td valign="middle" align="center">M</td><td valign="middle" align="center">buttock</td><td valign="middle" align="center">subcutis</td><td valign="middle" align="center">29&#x2009;&#xD7;&#x2009;17&#x2009;&#xD7;&#x2009;25&#xA0;mm</td><td valign="middle" align="center">FUS gene rearrangement (+) by FISH</td><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;)</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR7">7</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">9</td><td valign="middle" align="center">6</td><td valign="middle" align="center">F</td><td valign="middle" align="center">inguinal area</td><td valign="middle" align="center"/><td valign="middle" align="center">&#x3C6;35mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">recurrence 5 times, meta for lung 39&#xA0;years later</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">10</td><td valign="middle" align="center">9</td><td valign="middle" align="center">M</td><td valign="middle" align="center">neck</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">recurrence 7 times, meta 16&#xA0;years later</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">11</td><td valign="middle" align="center">6</td><td valign="middle" align="center">M</td><td valign="middle" align="center">deltoid</td><td valign="middle" align="center"/><td valign="middle" align="center">&#x3C6;33mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;)</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">12</td><td valign="middle" align="center">10</td><td valign="middle" align="center">F</td><td valign="middle" align="center">leg</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">with giant rosettes</td><td valign="middle" align="center"/><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">13</td><td valign="middle" align="center">13</td><td valign="middle" align="center">F</td><td valign="middle" align="center">back</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) at 36mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">14</td><td valign="middle" align="center">1.8</td><td valign="middle" align="center">M</td><td valign="middle" align="center">cheek</td><td valign="middle" align="center"/><td valign="middle" align="center">&#x3C6;80mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) 6mo</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">15</td><td valign="middle" align="center">13</td><td valign="middle" align="center">F</td><td valign="middle" align="center">arm</td><td valign="middle" align="center"/><td valign="middle" align="center">&#x3C6;30mm</td><td valign="middle" align="center">FUS (Ex6)/ CREB3L2 (Ex5) fusion gene by RT-PCR</td><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) at 34mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">16</td><td valign="middle" align="center">11</td><td valign="middle" align="center">M</td><td valign="middle" align="center">axilla</td><td valign="middle" align="center"/><td valign="middle" align="center">&#x3C6;60mm</td><td valign="middle" align="center">FUS (Ex6)/ CREB3L2 (Ex5) fusion gene by RT-PCR</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">17</td><td valign="middle" align="center">15</td><td valign="middle" align="center">M</td><td valign="middle" align="center">thorax</td><td valign="middle" align="center"/><td valign="middle" align="center">&#x3C6;30mm</td><td valign="middle" align="center">FUS (Ex6)/ CREB3L1 (Ex5) fusion gene by RT-PCR</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr valign="top"><td valign="middle" align="center" rowspan="2">18</td><td valign="middle" align="center" rowspan="2">13</td><td valign="middle" align="center" rowspan="2">M</td><td valign="middle" align="center" rowspan="2">foot</td><td valign="middle" align="center"/><td valign="middle" align="center" rowspan="2">&#x3C6;60mm</td><td valign="middle" align="center" rowspan="2">FUS (Ex6)/ CREB3L2 (Ex5) fusion gene by RT-PCR</td><td valign="middle" align="center"/><td valign="middle" align="center">pleural metastasis at 180, 186, and 203mos,</td><td valign="middle" align="center" rowspan="2">[<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr valign="top"><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">pleuropulmonary metastasis at 228 mos</td></tr><tr valign="top"><td valign="middle" align="center">19</td><td valign="middle" align="center">13</td><td valign="middle" align="center">F</td><td valign="middle" align="center">abdominal wall</td><td valign="middle" align="center">intramuscular</td><td valign="middle" align="center"/><td valign="middle" align="center">FUS (Ex6)/ CREB3L2 (Ex5) fusion gene by RT-PCR</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">20</td><td valign="middle" align="center">2</td><td valign="middle" align="center">F</td><td valign="middle" align="center">groin/vulva</td><td valign="middle" align="center">superficial</td><td valign="middle" align="center">&#x3C6;20mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) at 84mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">21</td><td valign="middle" align="center">3</td><td valign="middle" align="center">F</td><td valign="middle" align="center">knee/popliteal fossa</td><td valign="middle" align="center">superficial</td><td valign="middle" align="center">&#x3C6;42mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) at 60mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">22</td><td valign="middle" align="center">5</td><td valign="middle" align="center">M</td><td valign="middle" align="center">knee</td><td valign="middle" align="center">superficial</td><td valign="middle" align="center">&#x3C6;40mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) at 48mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">23</td><td valign="middle" align="center">6</td><td valign="middle" align="center">M</td><td valign="middle" align="center"/><td valign="middle" align="center">superficial</td><td valign="middle" align="center">&#x3C6;20mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">lost to follow up</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">24</td><td valign="middle" align="center">8</td><td valign="middle" align="center">M</td><td valign="middle" align="center">back</td><td valign="middle" align="center">superficial</td><td valign="middle" align="center">&#x3C6;30mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">local recurrence at 16mos, then lost to follow up</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">25</td><td valign="middle" align="center">10</td><td valign="middle" align="center">F</td><td valign="middle" align="center">lower leg</td><td valign="middle" align="center">superficial</td><td valign="middle" align="center">&#x3C6;16mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) at 48mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">26</td><td valign="middle" align="center">13</td><td valign="middle" align="center">M</td><td valign="middle" align="center">fore arm</td><td valign="middle" align="center">superficial</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) at 60mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr valign="top"><td valign="middle" align="center" rowspan="2">27</td><td valign="middle" align="center" rowspan="2">13</td><td valign="middle" align="center" rowspan="2">F</td><td valign="middle" align="center" rowspan="2">thigh</td><td valign="middle" align="center" rowspan="2"/><td valign="middle" align="center" rowspan="2"/><td valign="middle" align="center" rowspan="2">FUS (Ex6)-insertion-CREB3L2 (Ex5) fusion gene by RT-PCR</td><td valign="middle" align="center" rowspan="2"/><td valign="middle" align="center">local recurrence at 156, 192, 228, 252, 264,</td><td valign="middle" align="center" rowspan="2">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">and 276 mos</td></tr><tr valign="top"><td valign="middle" align="center">28</td><td valign="middle" align="center">12</td><td valign="middle" align="center">F</td><td valign="middle" align="center">buttock</td><td valign="middle" align="center"/><td valign="middle" align="center">&#x3C6;30mm</td><td valign="middle" align="center">FUS (Ex6)/ CREB3L2 (Ex5) fusion gene by RT-PCR</td><td valign="middle" align="center"/><td valign="middle" align="center">lost to follow up</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">29</td><td valign="middle" align="center">12</td><td valign="middle" align="center">M</td><td valign="middle" align="center">foot</td><td valign="middle" align="center"/><td valign="middle" align="center">&#x3C6;30mm</td><td valign="middle" align="center">FUS (Ex6)/ CREB3L2 (Ex5) fusion gene by RT-PCR</td><td valign="middle" align="center"/><td valign="middle" align="center">local recurrence at 19mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">30</td><td valign="middle" align="center">4</td><td valign="middle" align="center">M</td><td valign="middle" align="center">paravertebral</td><td valign="middle" align="center"/><td valign="middle" align="center">90&#x2009;&#xD7;&#x2009;80&#x2009;&#xD7;&#x2009;60&#xA0;mm</td><td valign="middle" align="center"/><td valign="middle" align="center">with giant rosettes</td><td valign="middle" align="center">local recurrence at 3mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR24">24</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">31</td><td valign="middle" align="center">13</td><td valign="middle" align="center">M</td><td valign="middle" align="center">buttock</td><td valign="middle" align="center">superficial</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">local recurrence at 24, 36, 60mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">32</td><td valign="middle" align="center">11</td><td valign="middle" align="center">F</td><td valign="middle" align="center">shoulder</td><td valign="middle" align="center">deep</td><td valign="middle" align="center">&#x3C6;45mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) 34mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">33</td><td valign="middle" align="center">14</td><td valign="middle" align="center">F</td><td valign="middle" align="center">inflaclavicular</td><td valign="middle" align="center"/><td valign="middle" align="center">&#x3C6;30mm</td><td valign="middle" align="center"/><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) 58mos</td><td valign="middle" align="center">[<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr valign="top"><td valign="middle" align="center" rowspan="2">34</td><td valign="middle" align="center" rowspan="2">4</td><td valign="middle" align="center" rowspan="2">M</td><td valign="middle" align="center" rowspan="2">thigh</td><td valign="middle" align="center" rowspan="2"/><td valign="middle" align="center" rowspan="2">&#x3C6;30mm</td><td valign="middle" align="center" rowspan="2"/><td valign="middle" align="center" rowspan="2"/><td valign="middle" align="center">local recurrence at 6, 36, and 84mos</td><td valign="middle" align="center" rowspan="2">[<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr valign="top"><td valign="middle" align="center">lung metastasis at 36, 84, and 98mos</td></tr><tr valign="top"><td valign="middle" align="center">this case</td><td valign="middle" align="center">5</td><td valign="middle" align="center">M</td><td valign="middle" align="center">Lower leg</td><td valign="middle" align="center">subfascial</td><td valign="middle" align="center">&#x3C6;26mm</td><td valign="middle" align="center">FUS (Ex6)/ CREB3L2 (Ex5) fusion gene by RT-PCR</td><td valign="middle" align="center"/><td valign="middle" align="center">(&#x2212;) at 4 mos</td><td valign="middle" align="center"/></tr></tbody></table><table-wrap-foot><p>Empty spaces: Data not available.</p></table-wrap-foot></table-wrap></p>
      <p>Considering both the smaller size and superficial location of LGFMS arising in correspondingly smaller infants and young adolescents, LGFMS in children might be noticed before becoming larger and invading into the fascia and skeletal muscles. Metastasis/local recurrence rates were 13%/38% in infants and 24%/41% in young adolescents, respectively, in our literature review. These rates are not significantly different from those previously reported in adult LGFMS [<xref ref-type="bibr" rid="CR19">19</xref>]. In addition, no differences in gene fusion events were noted between infants and young adolescents with LGFMS.</p>
      <p>Finally, we report a rare case of a 5-year-old Japanese boy with deeply located LGFMS in the lateral aspect of the lower leg. The superficial location of LGFMS in pediatric patients might be a reason for the relatively small tumor size in juvenile populations. Furthermore, superficial tumors are easily palpable and readily recognized by the patients and their parents.</p>
    </sec>
    <sec id="Sec4" sec-type="conclusion">
      <title>Conclusions</title>
      <p>Wide resection of the tumor in the limb reduces the recurrence rate, but also affecting the future functional outcome, especially in the childhood. Recent advance in molecular pathology is helpful to distinguish specific soft tissue tumors from their histologic mimics. It is important to avoid misdiagnosis and provide appropriate treatment with a help of molecular diagnosis.</p>
    </sec>
    <sec id="Sec5">
      <title>Consent</title>
      <p>Written informed consent was obtained from the parents of the patient for the publication of this report and accompanying images. The copy of the written consent is available for review by the Editor-in-Chief of this Journal.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>YS, TT and KK performed surgical treatment for this patient. AKA, MT, TS carried out the molecular genetic studies, participated in the sequence alignment. KM performed immunohistochemical analysis. AKA, AA, TY and TS drafted the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>This work was supported in part by a Grant-in-Aid for General Scientific Research from the Ministry of Education, Science, Sports and Culture (#26670286 to Tsuyoshi Saito, and #25861342 to Yoshiyuki Suehara), Tokyo, Japan.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sedrak</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Gardner</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Low-grade fibromyxoid sarcoma with nuclear pleomorphism arising in the subcutis of a child</article-title>
          <source>J Cutan Pathol</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>134</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="doi">10.1111/cup.12245</pub-id>
          <pub-id pub-id-type="pmid">24188507</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dobin</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Malone</surname>
              <given-names>VS</given-names>
            </name>
            <name>
              <surname>Lopez</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Donner</surname>
              <given-names>LR</given-names>
            </name>
          </person-group>
          <article-title>Unusual histologic variant of a low-grade fibromyxoid sarcoma in a 3-year-old boy with complex chromosomal translocations involving 7q34, 10q11.2, and 16p11.2 and rearrangement of the FUS gene</article-title>
          <source>Pediatr Dev Pathol</source>
          <year>2013</year>
          <volume>16</volume>
          <fpage>86</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.2350/12-07-1225-CR.1</pub-id>
          <pub-id pub-id-type="pmid">23075075</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Folpe</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Paull</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas</article-title>
          <source>Am J Surg Pathol</source>
          <year>2000</year>
          <volume>24</volume>
          <fpage>1353</fpage>
          <lpage>1360</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-200010000-00004</pub-id>
          <pub-id pub-id-type="pmid">11023096</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>ZH</given-names>
            </name>
            <name>
              <surname>Lv</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>XL</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>XG</given-names>
            </name>
          </person-group>
          <article-title>Low-grade fibromyxoid sarcoma: clinical study and case report</article-title>
          <source>J Oral Maxillofac Surg</source>
          <year>2010</year>
          <volume>68</volume>
          <fpage>873</fpage>
          <lpage>884</lpage>
          <pub-id pub-id-type="doi">10.1016/j.joms.2009.04.136</pub-id>
          <pub-id pub-id-type="pmid">20307771</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lau</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Lui</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Yau</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Cheung</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>EWSR1-CREB3L1 gene fusion: a novel alternative molecular aberration of low-grade fibromyxoid sarcoma</article-title>
          <source>Am J Surg Pathol</source>
          <year>2013</year>
          <volume>37</volume>
          <fpage>734</fpage>
          <lpage>738</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0b013e31827560f8</pub-id>
          <pub-id pub-id-type="pmid">23588368</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maretty-Nielsen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Baerentzen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dyrop</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Safwat</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Low-grade fibromyxoid sarcoma: Incidence, treatment strategy of metastases, and clinical significance of the FUS gene</article-title>
          <source>Sarcoma</source>
          <year>2013</year>
          <volume>&#x115F;</volume>
          <fpage>256280</fpage>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Krivanek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Low-grade fibromyxoid sarcoma, a deceptively benign tumor in a 5-year-old child</article-title>
          <source>Pediatr Surg Int</source>
          <year>2012</year>
          <volume>28</volume>
          <fpage>211</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="doi">10.1007/s00383-011-3024-z</pub-id>
          <pub-id pub-id-type="pmid">22130782</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doyle</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>M&#xF6;ller</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dal Cin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Mertens</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hornick</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>MUC4 is a highlysensitive and specific marker for low-grade fibromyxoid sarcoma</article-title>
          <source>Am J Surg Pathol</source>
          <year>2011</year>
          <volume>35</volume>
          <fpage>733</fpage>
          <lpage>741</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0b013e318210c268</pub-id>
          <pub-id pub-id-type="pmid">21415703</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M&#xF6;ller</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hornick</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Magnusson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Veerla</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Domanski</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Mertens</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>FUS-CREB3L2/L1-positive sarcomas show a specific gene expression profile with upregulation of CD24 and FOXL1</article-title>
          <source>Clin Cancer Res</source>
          <year>2011</year>
          <volume>17</volume>
          <fpage>2646</fpage>
          <lpage>2656</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0145</pub-id>
          <pub-id pub-id-type="pmid">21536545</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Folpe</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Billings</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>McKenney</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Nusrat</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Expression of claudin-1, a recently descrived tight junction-associated protein, distinguishes soft tissue perineurioma from potential mimics</article-title>
          <source>Am J Surg Pathol</source>
          <year>2002</year>
          <volume>26</volume>
          <fpage>1620</fpage>
          <lpage>1626</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-200212000-00010</pub-id>
          <pub-id pub-id-type="pmid">12459629</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thway</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Debic-Rychter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Calonje</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Claudin-1 is expressed in perineuroma-like low-grade fibromyxoid sarcoma</article-title>
          <source>Hum Pathol</source>
          <year>2009</year>
          <volume>40</volume>
          <fpage>1586</fpage>
          <lpage>1590</lpage>
          <pub-id pub-id-type="doi">10.1016/j.humpath.2009.04.003</pub-id>
          <pub-id pub-id-type="pmid">19540561</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Odem</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Oroszi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bernreuter</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Grammatopoulou</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lauer</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Greenberg</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Vogler</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Batanian</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Deceptively benign low-grade fibromyxoid sarcoma: array-comparative genomic hybridization decodes the diagnosis</article-title>
          <source>Hum Pathol</source>
          <year>2013</year>
          <volume>44</volume>
          <fpage>145</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.1016/j.humpath.2012.07.021</pub-id>
          <pub-id pub-id-type="pmid">23089491</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Panagopoulos</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Storlazzi</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Domanski</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Wejde</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brosj&#xF6;</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Rydholm</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Isaksson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mandahl</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mertens</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma</article-title>
          <source>Genes Chromosomes Cancer</source>
          <year>2004</year>
          <volume>40</volume>
          <fpage>218</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="doi">10.1002/gcc.20037</pub-id>
          <pub-id pub-id-type="pmid">15139001</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsuyama</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hisaoka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shimajiri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishida</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fukunaga</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fukuhara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Minato</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yonezawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kuroda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamasaki</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Toyoshima</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Molecular detection of FUS-CREB3L2 fusion transcripts in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens</article-title>
          <source>Am J Surg Pathol</source>
          <year>2006</year>
          <volume>30</volume>
          <fpage>1077</fpage>
          <lpage>1084</lpage>
          <pub-id pub-id-type="doi">10.1097/01.pas.0000209830.24230.1f</pub-id>
          <pub-id pub-id-type="pmid">16931951</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Guan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review</article-title>
          <source>Diagn Pathol</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>147</fpage>
          <pub-id pub-id-type="doi">10.1186/1746-1596-8-147</pub-id>
          <pub-id pub-id-type="pmid">24034896</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>XY</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>QC</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>EH</given-names>
            </name>
          </person-group>
          <article-title>Sclerosing rhabdomyosarcoma presenting in the masseter muscle: a case report</article-title>
          <source>Diagn Pathol</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>18</fpage>
          <pub-id pub-id-type="doi">10.1186/1746-1596-8-18</pub-id>
          <pub-id pub-id-type="pmid">23379991</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martorell</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ortiz</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Testicular fusocellular rhabdomyosarcoma as a metastasis of elbow sclerosing rhabdomyosarcoma: a clinicopathologic, immunohistochemical and molecular study of one case</article-title>
          <source>Diagn Pathol</source>
          <year>2010</year>
          <volume>5</volume>
          <fpage>52</fpage>
          <pub-id pub-id-type="doi">10.1186/1746-1596-5-52</pub-id>
          <pub-id pub-id-type="pmid">20701800</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mignemi</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Itani</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Fasig</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Keedy</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Hande</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Whited</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Homlar</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Correa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Coffin</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Halpern</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Holt</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Schoenecker</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Cates</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-&#x3B2;, COX2 and sex steroid receptors</article-title>
          <source>Cancer Sci</source>
          <year>2012</year>
          <volume>103</volume>
          <fpage>2173</fpage>
          <lpage>2180</lpage>
          <pub-id pub-id-type="doi">10.1111/cas.12037</pub-id>
          <pub-id pub-id-type="pmid">23035734</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>HL</given-names>
            </name>
          </person-group>
          <article-title>Low-grade fibromyxoid sarcoma: a clinicopathologic study of 33 cases with long-term follow-up</article-title>
          <source>Am J Surg Pathol</source>
          <year>2011</year>
          <volume>35</volume>
          <fpage>1450</fpage>
          <lpage>1462</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0b013e31822b3687</pub-id>
          <pub-id pub-id-type="pmid">21921785</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rekhi</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Deshmukh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jambhekar</surname>
              <given-names>NA</given-names>
            </name>
          </person-group>
          <article-title>Low-grade fibromyxoid sarcoma: a clinicopathologic study of 18 cases, including histopathologic relationship with sclerosing epithelioid fibrosarcoma in a subset of cases</article-title>
          <source>Ann Diagn Pathol</source>
          <year>2011</year>
          <volume>15</volume>
          <fpage>303</fpage>
          <lpage>311</lpage>
          <pub-id pub-id-type="doi">10.1016/j.anndiagpath.2011.02.005</pub-id>
          <pub-id pub-id-type="pmid">21550274</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guillou</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Benhattar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gengler</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ranch&#xE8;re-Vince</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Collin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Terrier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Terrier-Lacombe</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Leroux</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marqu&#xE8;s</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Aubain Somerhausen Nde</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Keslair</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pedeutour</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Coindre</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group</article-title>
          <source>Am J Surg Pathol</source>
          <year>2007</year>
          <volume>31</volume>
          <fpage>1387</fpage>
          <lpage>1402</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0b013e3180321959</pub-id>
          <pub-id pub-id-type="pmid">17721195</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Billings</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Giblen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fanburg-Smith</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Superficial low-grade fibromyxoid sarcoma (Evans Tumor): a clinicopathologic analysis of 19 cases with a unique observation in the pediatric Population</article-title>
          <source>Am J Surg Pathol</source>
          <year>2005</year>
          <volume>29</volume>
          <fpage>204</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="doi">10.1097/01.pas.0000146014.22624.8e</pub-id>
          <pub-id pub-id-type="pmid">15644777</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mertens</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Antonescu</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Coindre</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Colecchia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Domanski</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Downs-Kelly</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Goldblum</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Guillou</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rosai</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sciot</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mandahl</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Panagopoulos</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene</article-title>
          <source>Lab Invest</source>
          <year>2005</year>
          <volume>85</volume>
          <fpage>408</fpage>
          <lpage>415</lpage>
          <pub-id pub-id-type="doi">10.1038/labinvest.3700230</pub-id>
          <pub-id pub-id-type="pmid">15640831</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rando</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Buonuomo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>D&#x2019;Urzo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vecchio</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Caldarelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pintus</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Fibromyxoid sarcoma in a 4-year-old boy: case report and review of the literature</article-title>
          <source>Pediatr Surg Int</source>
          <year>2005</year>
          <volume>21</volume>
          <fpage>311</fpage>
          <lpage>312</lpage>
          <pub-id pub-id-type="doi">10.1007/s00383-005-1400-2</pub-id>
          <pub-id pub-id-type="pmid">15747125</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takahira</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kawaguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tamiya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsuneyoshi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Low-grade fibromyxoid sarcoma versus low-grade myxofibrosarcoma in the extremities and trunk. A comparison of clinicopathological and immunohistochemical features</article-title>
          <source>Histopathology</source>
          <year>2004</year>
          <volume>45</volume>
          <fpage>29</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2559.2004.01886.x</pub-id>
          <pub-id pub-id-type="pmid">15228441</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lane</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Hyalinizing spindle cell tumor with giant rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma</article-title>
          <source>Am J Surg Pathol</source>
          <year>1997</year>
          <volume>21</volume>
          <fpage>1481</fpage>
          <lpage>1488</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-199712000-00011</pub-id>
          <pub-id pub-id-type="pmid">9414192</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Canpolat</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Corpron</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Andrassy</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Eifel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Elidemir</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Raney</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Fibromyxoid sarcoma in a four-year-old child: case report and review of the literature</article-title>
          <source>Med Pediatr Oncol</source>
          <year>1996</year>
          <volume>27</volume>
          <fpage>561</fpage>
          <lpage>564</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1096-911X(199612)27:6&lt;561::AID-MPO10&gt;3.0.CO;2-B</pub-id>
          <pub-id pub-id-type="pmid">8888818</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rose</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tamvakopoulos</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Dulay</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pollock</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Skinner</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Briggs</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cannon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The clinical significance of the FUS-CREB3L2 translocation in low-grade fibromyxoid sarcoma</article-title>
          <source>J Orthop Surg Res</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>15</fpage>
          <pub-id pub-id-type="doi">10.1186/1749-799X-6-15</pub-id>
          <pub-id pub-id-type="pmid">21406083</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
